SCHEMBL1746725

SCHEMBL1746725

CCOC(=O)CCCc1cccc(OC2CCc3ccccc32)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFRA3 O60609 2/20 0.50
GFRA2 O00451 1/20 0.50
FFAR1 O14842 4/20 0.46
PPARA Q07869 3/20 0.45
PPARG P37231 2/20 0.45
ALOX5 P09917 1/20 0.43
RET P07949 2/20 0.42
CYP4F2 P78329 1/20 0.40
CYP4A11 Q02928 1/20 0.40
NAMPT P43490 1/20 0.39
CCR8 P51685 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745124 0.86 GFRA3 (0.52) GFRA3GFRA2FFAR1RETCYP1A2
SCHEMBL12019248 0.78 FFAR1 (0.51) GFRA3GFRA2FFAR1MAPTPOLB
SCHEMBL1747049 0.77 GFRA3 (0.58) GFRA3GFRA2FFAR1RET
SCHEMBL1746652 0.77 GFRA3 (0.63) GFRA3GFRA2FFAR1RET
SCHEMBL2351642 0.77 FFAR1 (0.41) FFAR1CYP4F2CYP4A11ALDH1A1
SCHEMBL1744666 0.76 GFRA3 (0.53) GFRA3GFRA2FFAR1RET
SCHEMBL1856638 0.75 PPARA (0.59) PPARAPPARGALOX5KDM4EALDH1A1
SCHEMBL1744583 0.75 GFRA3 (0.49) GFRA3GFRA2FFAR1RET
SCHEMBL12017998 0.74 FFAR1 (0.47) GFRA3GFRA2FFAR1RET
SCHEMBL1746731 0.73 FFAR1 (0.45) GFRA3GFRA2FFAR1RETSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR GFRA3 412/4885GFRA2 338/4885FFAR1 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.